| Budget Amount *help |
¥1,670,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2008: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2007: ¥500,000 (Direct Cost: ¥500,000)
|
|---|
| Research Abstract |
In a cirrhotic liver, the regenerative ability and specific functions are impaires ; a hepatic resection increases the possibility of postoperative liver failure. A truncated type II transforming growth factor-β receptor (TβTR), which specifically inhibits TGF-β signaling as a dominant-negative receptor, appears to prevent the progression of liver fibrosis. We demonstrated the therapeutic efficacy of adenovirus-mediated TβTR gene transducation after partial hepatectomy for liver cirrhosis. Rats were treated with dimethylnitrosamine for 3 weeks, and they all had severe cirrhosis. After the 10% partial hepatectomy in rats of this model, we injected PBS, AdLacZ, and Ad TβTR, into the portal vein, which was followed by an additionl 2-week dimethylnitrosamine treatment. On histologic examination, fibrotic tissue had decreased in the livers of the Ad TβTR -treated rats compared with rats that were treated by PBS and AdLacZ. Ad TβTR treatment improved the survival rate after a partial hepatectomy. Our results suggest that the TβTR gene therapy may increase the possibility of hepatectomy in a cirrhotic liver by improving fibrosis, hepatic function, and hepatocyte regeneration.
|
